MCID: HMN021
MIFTS: 52

Human T-Cell Leukemia Virus Type 1 malady

Categories: Rare diseases, Immune diseases, Cancer diseases, Skin diseases, Blood diseases

Aliases & Classifications for Human T-Cell Leukemia Virus Type 1

Aliases & Descriptions for Human T-Cell Leukemia Virus Type 1:

Name: Human T-Cell Leukemia Virus Type 1 50
Human T Lymphotropic Virus Type 1 50
Htlv-1 50

Classifications:



Summaries for Human T-Cell Leukemia Virus Type 1

NIH Rare Diseases : 50 human t-cell leukemia virus, type 1 (htlv-1) is a retroviral infection that affect the t cells (a type of white blood cell). although this virus generally causes no signs or symptoms, some affected people may later develop adult t-cell leukemia (atl), htlv-1 associated myelopathy/tropical spastic paraparesis (ham/tsp) or other medical conditions. htlv-1 is spread by blood transfusions, sexual contact and sharing needles. it can also be spread from mother to child during birth or breast-feeding. there is no cure or treatment for htlv-1 and it is considered a lifelong condition; however, most (95%) infected people remain asymptomatic (show no symptoms) throughout life. last updated: 12/10/2014

MalaCards based summary : Human T-Cell Leukemia Virus Type 1, also known as human t lymphotropic virus type 1, is related to htlv-1 associated myelopathy/tropical spastic paraparesis and infective dermatitis associated with htlv-1. An important gene associated with Human T-Cell Leukemia Virus Type 1 is CRTC2 (CREB Regulated Transcription Coactivator 2), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Daclizumab and Immunoglobulins have been mentioned in the context of this disorder. Affiliated tissues include t cells, breast and monocytes, and related phenotypes are Decreased Hepatitis C Virus pseudoparticles (HCVpp and cellular

Wikipedia : 71 Human T-cell lymphotropic virus type 1 or human T-lymphotropic virus type 1 (HTLV-I), also called the... more...

Related Diseases for Human T-Cell Leukemia Virus Type 1

Diseases in the T-Cell Leukemia family:

Adult T-Cell Leukemia Acute T Cell Leukemia
Human T-Cell Leukemia Virus Type 1 Human T-Cell Leukemia Virus Type 2
Human T-Cell Leukemia Virus Type 3 Leukemia, B-Cell, Chronic
Leukemia, T-Cell, Chronic

Diseases related to Human T-Cell Leukemia Virus Type 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 44)
id Related Disease Score Top Affiliating Genes
1 htlv-1 associated myelopathy/tropical spastic paraparesis 11.3
2 infective dermatitis associated with htlv-1 11.3
3 t-cell leukemia 11.2
4 leukemia 11.2
5 adult t-cell leukemia 10.5
6 lymphoma 10.4
7 tropical spastic paraparesis 10.2
8 spastic paraparesis 10.2
9 spasticity 10.2
10 nephronophthisis 7 10.1 CREB1 CREBBP EP300
11 hiv-1 10.1
12 bilateral multicystic dysplastic kidney 10.1 ATF1 CREB1
13 primary eye hypotony 10.0 CDK4 CREBBP
14 hepatitis c 10.0
15 hepatitis c virus 10.0
16 hepatitis 10.0
17 mini stroke 10.0 CREB1 CREBBP EP300 JUN
18 hutchinson incisors 10.0 CNTN2 CREB1 CREBBP EP300 NFKB1
19 anus basaloid carcinoma 10.0 CNTN2 CREB1 CRTC2 EP300 GLI2
20 pulmonary immaturity 10.0 ATF1 CDK4 CREB1
21 rheumatoid arthritis 9.9
22 lung cancer 9.9
23 arthropathy 9.9
24 borna disease 9.9
25 retinoblastoma 9.9
26 neuronitis 9.9
27 herpes simplex 9.9
28 arthritis 9.9
29 glioblastoma 9.9
30 chronic lymphocytic leukemia 9.9
31 large granular lymphocyte leukemia 9.9
32 t-cell large granular lymphocyte leukemia 9.9
33 pituitary tumors 9.9
34 gastric lymphoma 9.9
35 endotheliitis 9.9
36 graves' disease 9.9
37 uveitis 9.9
38 myotubular myopathy, x-linked 9.9 CDK2 CDK4 CDKN1A
39 extraocular retinoblastoma 9.8 CDK2 CDK4 CDKN1A
40 integumentary system benign neoplasm 9.8 CDK2 CDK4 CDKN1A
41 post-surgical hypoinsulinemia 9.7 CDK2 CDK4 CDKN1A
42 thoracic outlet syndrome 9.7 CDK2 CDK4 CDKN1A
43 split-hand/foot malformation with long bone deficiency 1 8.7 CDK2 CDK4 CDKN1A CHUK CREB1 CREBBP
44 hurst hallam hockey syndrome 8.1 ATF1 CDK2 CDK4 CDKN1A CHUK CNTN2

Graphical network of the top 20 diseases related to Human T-Cell Leukemia Virus Type 1:



Diseases related to Human T-Cell Leukemia Virus Type 1

Symptoms & Phenotypes for Human T-Cell Leukemia Virus Type 1

GenomeRNAi Phenotypes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased Hepatitis C Virus pseudoparticles (HCVpp GR00234-A-1 8.92 CDK2 CDK4 CHUK IKBKB

MGI Mouse Phenotypes related to Human T-Cell Leukemia Virus Type 1:

44 (show all 21)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.37 EP300 GLI2 IKBKB JUN NFKB1 CDK2
2 homeostasis/metabolism MP:0005376 10.34 CHUK CREB1 CREBBP CRTC2 CRTC3 EP300
3 growth/size/body region MP:0005378 10.33 IKBKB JUN NFKB1 CDK2 CDK4 CDKN1A
4 endocrine/exocrine gland MP:0005379 10.3 CDK2 CDK4 CDKN1A CHUK CREB1 CREBBP
5 embryo MP:0005380 10.27 CDK2 CDK4 CDKN1A CHUK CREB1 CREBBP
6 cardiovascular system MP:0005385 10.25 CDK2 CDK4 CDKN1A CHUK CREB1 CREBBP
7 mortality/aging MP:0010768 10.21 NFKB1 CDK2 CDK4 CDKN1A CHUK CREB1
8 hematopoietic system MP:0005397 10.19 CDK2 CDK4 CDKN1A CHUK CREBBP EP300
9 digestive/alimentary MP:0005381 10.18 CDK4 CDKN1A CHUK CREBBP EP300 GLI2
10 immune system MP:0005387 10.16 CDK2 CDK4 CDKN1A CHUK CREBBP EP300
11 liver/biliary system MP:0005370 10.16 CDK2 CDK4 CDKN1A CHUK CREBBP CRTC2
12 integument MP:0010771 10.15 CDK2 CDK4 CDKN1A CHUK CREBBP GLI2
13 muscle MP:0005369 10.1 NFKB1 CDK2 CDK4 CDKN1A CREB1 CREBBP
14 craniofacial MP:0005382 10.06 NFKB1 CDKN1A CHUK CREBBP EP300 GLI2
15 nervous system MP:0003631 10.06 CDKN1A CHUK CNTN2 CREB1 CREBBP EP300
16 limbs/digits/tail MP:0005371 10.02 CDKN1A CHUK CNTN2 CREBBP CRTC3 GLI2
17 normal MP:0002873 9.86 CDK4 CREB1 CREBBP EP300 GLI2 IKBKB
18 neoplasm MP:0002006 9.85 CDK2 CDK4 CDKN1A CHUK CREBBP EP300
19 respiratory system MP:0005388 9.76 CDKN1A CHUK CREB1 CREBBP EP300 GLI2
20 skeleton MP:0005390 9.56 GLI2 JUN NFKB1 CDKN1A CHUK CREB1
21 vision/eye MP:0005391 9.17 CDK2 CDK4 CDKN1A CHUK EP300 GLI2

Drugs & Therapeutics for Human T-Cell Leukemia Virus Type 1

Drugs for Human T-Cell Leukemia Virus Type 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Daclizumab Approved, Investigational Phase 4,Phase 1,Phase 2 152923-56-3
2 Immunoglobulins Phase 4,Phase 1,Phase 2
3 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1
4 Antibodies Phase 4,Phase 1,Phase 2
5 Immunoglobulin G Phase 4,Phase 1,Phase 2
6
Cyclosporine Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 79217-60-0, 59865-13-3 5284373 6435893
7
Zidovudine Approved Phase 2, Phase 3,Phase 1,Early Phase 1 30516-87-1 35370
8
Lamivudine Approved, Investigational Phase 2, Phase 3 134678-17-4 60825
9
Valproic Acid Approved, Investigational Phase 3,Phase 1,Phase 2 99-66-1 3121
10
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
11
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 22916-47-8 4189
12
Ritonavir Approved, Investigational Phase 2, Phase 3 155213-67-5 392622
13
Lopinavir Approved Phase 2, Phase 3 192725-17-0 92727
14 Neurotransmitter Agents Phase 3,Phase 1,Phase 2
15 HIV Integrase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
16 Anti-HIV Agents Phase 2, Phase 3, Phase 1, Early Phase 1
17 Anti-Infective Agents Phase 2, Phase 3, Phase 1, Early Phase 1
18 Anticonvulsants Phase 3,Phase 1,Phase 2
19 Integrase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
20 Antimetabolites Phase 2, Phase 3,Phase 1,Early Phase 1
21 Raltegravir Potassium Phase 2, Phase 3,Phase 1,Early Phase 1
22 Anti-Retroviral Agents Phase 2, Phase 3, Phase 1, Early Phase 1
23 Antirheumatic Agents Phase 2, Phase 3,Phase 1,Early Phase 1
24 Calcineurin Inhibitors Phase 2, Phase 3,Phase 1
25 Antiviral Agents Phase 2, Phase 3, Phase 1, Early Phase 1
26
protease inhibitors Phase 2, Phase 3
27 GABA Agents Phase 3,Phase 1,Phase 2
28 HIV Protease Inhibitors Phase 2, Phase 3
29 Nucleic Acid Synthesis Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
30 Dermatologic Agents Phase 2, Phase 3,Phase 1
31 Tranquilizing Agents Phase 3,Phase 1,Phase 2
32 Vasodilator Agents Phase 3
33 Phosphodiesterase Inhibitors Phase 3
34 Platelet Aggregation Inhibitors Phase 3
35 Protective Agents Phase 3,Phase 2
36 Antifungal Agents Phase 2, Phase 3,Phase 1
37 Psychotropic Drugs Phase 3,Phase 1,Phase 2
38 Antimanic Agents Phase 3,Phase 1,Phase 2
39 Radiation-Protective Agents Phase 3
40 Reverse Transcriptase Inhibitors Phase 2, Phase 3,Phase 1,Early Phase 1
41 Antioxidants Phase 3
42 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
43 Cytochrome P-450 CYP3A Inhibitors Phase 2, Phase 3
44 Cytochrome P-450 Enzyme Inhibitors Phase 2, Phase 3
45
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
46
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
47
Vincristine Approved, Investigational Phase 2,Phase 1 2068-78-2, 57-22-7 5978
48
Cyclophosphamide Approved, Investigational Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
49
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
50
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078

Interventional clinical trials:

(show top 50) (show all 124)
id Name Status NCT ID Phase
1 Pilot Study of Combination Therapy With CHOP-Zenapax (CHOP-daclizumab) Completed NCT01418430 Phase 4
2 Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Unknown status NCT01343355 Phase 2, Phase 3
3 Zidovudine Plus Lamivudine in HTLV-I-associated Myelopathy: a Randomised Trial Completed NCT00272480 Phase 2, Phase 3
4 Use of Pentoxifylline in Human T-lymphotropic Virus Type-1 (HTLV-1) Diseases Completed NCT01472263 Phase 3
5 Ciclosporin in HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP) Completed NCT00773292 Phase 2, Phase 3
6 Use Of Valproid Acid To Treat Tropical Spastic Paraparesis/HTLV-1-Associated Myelopathy (TSP/HAM) Completed NCT00681980 Phase 3
7 Antiretroviral Regimens Containing Raltegravir for Prophylaxis of Mother-to-child-transmission of HIV Infection Recruiting NCT01854762 Phase 2, Phase 3
8 Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load Unknown status NCT01620736 Phase 2
9 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
10 Rituximab in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Unknown status NCT01044745 Phase 2
11 Recombinant Human Interferon Beta-1a (Avonex) for the Treatment of Patients With HTLV-1-Associated Myelopathy (HAM) Completed NCT00001785 Phase 2
12 Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma Completed NCT00041327 Phase 2
13 Lenalidomide in HTLV-1 Adult T-Cell Leukemia Completed NCT01274533 Phase 2
14 Anti-Tac for Treatment of Leukemia Completed NCT00001941 Phase 1, Phase 2
15 EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma Completed NCT01000285 Phase 1, Phase 2
16 Campath-1H for Treating Adult T-Cell Leukemia/Lymphoma Completed NCT00061048 Phase 2
17 Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia Completed NCT00117845 Phase 2
18 Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies Completed NCT00481871 Phase 1, Phase 2
19 Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation Completed NCT00005606 Phase 2
20 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2
21 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer Completed NCT00049504 Phase 2
22 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies Completed NCT01427881 Phase 2
23 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2
24 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma Completed NCT01110135 Phase 2
25 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2
26 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2
27 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma Completed NCT00006473 Phase 2
28 Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer Completed NCT00589563 Phase 2
29 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2
30 Ruxolitinib for Adult T-Cell Leukemia Recruiting NCT01712659 Phase 2
31 Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma Recruiting NCT02631746 Phase 2
32 Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Recruiting NCT03075553 Phase 2
33 Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies Recruiting NCT00002663 Phase 1, Phase 2
34 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies Recruiting NCT01760655 Phase 2
35 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies Recruiting NCT01839916 Phase 2
36 Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia Active, not recruiting NCT00924170 Phase 1, Phase 2
37 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant Active, not recruiting NCT00078858 Phase 1, Phase 2
38 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma Active, not recruiting NCT01075321 Phase 1, Phase 2
39 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma Active, not recruiting NCT00918333 Phase 1, Phase 2
40 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer Active, not recruiting NCT00006251 Phase 1, Phase 2
41 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer Active, not recruiting NCT00089011 Phase 2
42 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Active, not recruiting NCT01529827 Phase 2
43 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies Active, not recruiting NCT00040846 Phase 2
44 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma Active, not recruiting NCT01261247 Phase 2
45 Zidovudine, Interferon Alfa-2b, and PEG-Interferon Alfa-2b in Treating Patients With Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia/Lymphoma Terminated NCT00854581 Phase 1, Phase 2
46 The HAM Infliximab Study Terminated NCT00823641 Phase 2
47 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant Terminated NCT01419795 Phase 2
48 Ipilimumab and Local Radiation Therapy in Treating Patients With Recurrent Melanoma, Non-Hodgkin Lymphoma, Colon, or Rectal Cancer Terminated NCT01769222 Phase 1, Phase 2
49 Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation Terminated NCT01116232 Phase 2
50 Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies Terminated NCT00776373 Phase 1, Phase 2

Search NIH Clinical Center for Human T-Cell Leukemia Virus Type 1

Genetic Tests for Human T-Cell Leukemia Virus Type 1

Anatomical Context for Human T-Cell Leukemia Virus Type 1

MalaCards organs/tissues related to Human T-Cell Leukemia Virus Type 1:

39
T Cells, Breast, Monocytes, Liver, Testes, Bone, B Cells

Publications for Human T-Cell Leukemia Virus Type 1

Articles related to Human T-Cell Leukemia Virus Type 1:

(show top 50) (show all 442)
id Title Authors Year
1
Erratum to: Endemic impact of human T cell leukemia virus type 1 screening in bone allografts. ( 27770291 )
2016
2
Functional Comparison of HBZ and the Related APH-2 Protein Provides Insight into Human T-Cell Leukemia Virus Type 1 Pathogenesis. ( 26819304 )
2016
3
Induction of Cell Death in Growing Human T-Cells and Cell Survival in Resting Cells in Response to the Human T-Cell Leukemia Virus Type 1 Tax. ( 26829041 )
2016
4
Endemic impact of human T cell leukemia virus type 1 screening in bone allografts. ( 27677902 )
2016
5
The Tax-Inducible Actin-Bundling Protein Fascin Is Crucial for Release and Cell-to-Cell Transmission of Human T-Cell Leukemia Virus Type 1 (HTLV-1). ( 27776189 )
2016
6
Permissive Sense and Antisense Transcription from the 5' and 3' Long Terminal Repeats of Human T-Cell Leukemia Virus Type 1. ( 26792732 )
2016
7
Human T-cell leukemia virus type 1 (HTLV-1) Tax1 oncoprotein but not HTLV-2 Tax2 induces the expression of OX40 ligand by interacting with p52/p100 and RelB. ( 26739459 )
2016
8
Enhanced Stabilization of MCL1 by the Human T-Cell Leukemia Virus Type 1 bZIP Factor Is Modulated by Blocking the Recruitment of Cullin 1 to the SCF Complex. ( 27697867 )
2016
9
Suppression of Type I Interferon Production by Human T-Cell Leukemia Virus Type 1 Oncoprotein Tax through Inhibition of IRF3 Phosphorylation. ( 26819312 )
2016
10
Impact of human T-cell leukemia virus type 1 on living donor liver transplantation: a multi-center study in Japan. ( 26996829 )
2016
11
Expression of Alternatively Spliced Human T-Cell Leukemia Virus Type 1 mRNAs Is Influenced by Mitosis and by a Novel cis-Acting Regulatory Sequence. ( 26581997 )
2016
12
Akt Pathway Activation by Human T-cell Leukemia Virus Type 1 Tax Oncoprotein. ( 26324707 )
2015
13
Standardization of Quantitative PCR for Human T-Cell Leukemia Virus Type 1 in Japan: a Collaborative Study. ( 26292315 )
2015
14
Human T-cell leukemia virus type 1 (HTLV-1) tax requires CADM1/TSLC1 for inactivation of the NF-I_B inhibitor A20 and constitutive NF-I_B signaling. ( 25774694 )
2015
15
Analysis of human T-cell leukemia virus type 1 particles by using cryo-electron tomography. ( 25473052 )
2015
16
Viral Source-Independent High Susceptibility of Dendritic Cells to Human T-Cell Leukemia Virus Type 1 Infection Compared to That of T Lymphocytes. ( 26269171 )
2015
17
Human T Cell Leukemia Virus Type 1 Infection of the Three Monocyte Subsets Contributes to Viral Burden in Humans. ( 26608313 )
2015
18
Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis. ( 26174324 )
2015
19
Prevalence of human T-cell leukemia virus type 1 carrier in Japanese pregnant women in 2013. ( 25883717 )
2015
20
Regulation of the tumor marker Fascin by the viral oncoprotein Tax of human T-cell leukemia virus type 1 (HTLV-1) depends on promoter activation and on a promoter-independent mechanism. ( 26363219 )
2015
21
Modes of Human T Cell Leukemia Virus Type 1 Transmission, Replication and Persistence. ( 26198240 )
2015
22
SIRT1 Suppresses Human T-Cell Leukemia Virus Type 1 Transcription. ( 26063426 )
2015
23
Characterizing the protonation states of the catalytic residues in apo and substrate-bound human T-cell leukemia virus type 1 protease. ( 25889320 )
2015
24
Human T-cell leukemia virus type 1 Tax oncoprotein represses the expression of the BCL11B tumor suppressor in T-cells. ( 25613934 )
2015
25
miR-28-3p is a cellular restriction factor that inhibits human T cell leukemia virus, type 1 (HTLV-1) replication and virus infection. ( 25568327 )
2015
26
Advanced human T-cell leukemia virus type 1 carriersA and early-stage indolent adult T-cell leukemia-lymphoma are indistinguishable based on CADM1 positivity in flow cytometry. ( 25703103 )
2015
27
Small noncoding RNAs in cells transformed by human T-cell leukemia virus type 1: a role for a tRNA fragment as a primer for reverse transcriptase. ( 24403582 )
2014
28
Human T-cell leukemia virus type 1 and Foxp3 expression: viral strategy in vivo. ( 24792037 )
2014
29
Palmitoylation and p8-mediated human T-cell leukemia virus type 1 transmission. ( 24284316 )
2014
30
Human T-cell leukemia virus type 1 Tax-deregulated autophagy pathway and c-FLIP expression contribute to resistance against death receptor-mediated apoptosis. ( 24352466 )
2014
31
Reevaluation of confirmatory tests for human T-cell leukemia virus Type 1 using a luciferase immunoprecipitation system in blood donors. ( 25363675 )
2014
32
CD69 overexpression by human T-cell leukemia virus type 1 Tax transactivation. ( 23507197 )
2013
33
Virological and immunological mechanisms in the pathogenesis of human T-cell leukemia virus type 1. ( 23606621 )
2013
34
Human T-cell leukemia virus type 1 Tax protein interacts with and mislocalizes the PDZ domain protein MAGI-1. ( 23279616 )
2013
35
p53 dysfunction precedes the activation of nuclear factor-I_B during disease progression in mice expressing Tax, a human T-cell leukemia virus type 1 oncoprotein. ( 23633516 )
2013
36
The four and a half LIM family members are novel interactants of the human T-cell leukemia virus type 1 Tax oncoprotein. ( 23616667 )
2013
37
Group I p21-activated kinases facilitate Tax-mediated transcriptional activation of the human T-cell leukemia virus type 1 long terminal repeats. ( 23622267 )
2013
38
Lack of recall response to Tax in ATL and HAM/TSP patients but not in asymptomatic carriers of human T-cell leukemia virus type 1. ( 23888327 )
2013
39
Inhibitory effect of chondroitin sulfate type E on the binding step of human T-cell leukemia virus type 1. ( 23033806 )
2013
40
Failure in activation of the canonical NF-I_B pathway by human T-cell leukemia virus type 1 Tax in non-hematopoietic cell lines. ( 23791017 )
2013
41
Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. ( 24060211 )
2013
42
HSP90 protects the human T-cell leukemia virus type 1 (HTLV-1) tax oncoprotein from proteasomal degradation to support NF-I_B activation and HTLV-1 replication. ( 24109220 )
2013
43
Host restriction factor SAMHD1 limits human T cell leukemia virus type 1 infection of monocytes via STING-mediated apoptosis. ( 24139400 )
2013
44
The cellular autophagy pathway modulates human T-cell leukemia virus type 1 replication. ( 23175371 )
2013
45
LKB1 tumor suppressor and salt-inducible kinases negatively regulate human T-cell leukemia virus type 1 transcription. ( 23577667 )
2013
46
Molecular study of HBZ and gp21 human T cell leukemia virus type 1 proteins isolated from different clinical profile infected individuals. ( 23800288 )
2013
47
An altered maturation and adhesion phenotype of dendritic cells in diseased individuals compared to asymptomatic carriers of human T cell leukemia virus type 1. ( 23750452 )
2013
48
Entry of human T-cell leukemia virus type 1 is augmented by heparin sulfate proteoglycans bearing short heparin-like structures. ( 22238310 )
2012
49
Human T-cell leukemia virus type 1 (HTLV-1) bZIP factor requires cellular transcription factor JunD to upregulate HTLV-1 antisense transcription from the 3' long terminal repeat. ( 22696638 )
2012
50
Activation of mTOR by human T-cell leukemia virus type 1 Tax is important for the transformation of mouse T cells to interleukin-2-independent growth. ( 22010857 )
2012

Variations for Human T-Cell Leukemia Virus Type 1

Expression for Human T-Cell Leukemia Virus Type 1

Search GEO for disease gene expression data for Human T-Cell Leukemia Virus Type 1.

Pathways for Human T-Cell Leukemia Virus Type 1

Pathways related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show top 50) (show all 179)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
14.26 ATF1 CDK2 CDK4 CDKN1A CHUK CREB1
2
Show member pathways
13.96 ATF1 CDK2 CDK4 CDKN1A CHUK CREB1
3
Show member pathways
13.82 CDKN1A CHUK CREB1 CREBBP EP300 IKBKB
4
Show member pathways
13.8 CDK2 CDK4 CDKN1A CHUK CREB1 CREBBP
5
Show member pathways
13.75 CDKN1A CHUK CREB1 CREBBP EP300 IKBKB
6
Show member pathways
13.64 CDKN1A CHUK CREB1 CREBBP EP300 IKBKB
7
Show member pathways
13.58 CDK4 CNTN2 CREB1 CREBBP EP300 JUN
8
Show member pathways
13.32 ATF1 CHUK CREB1 CREBBP EP300 IKBKB
9
Show member pathways
13.26 CDK2 CDK4 CDKN1A CREBBP EP300 JUN
10
Show member pathways
13.1 CHUK CREBBP EP300 IKBKB JUN NFKB1
11
Show member pathways
13.07 CHUK CREBBP IKBKB JUN NFKB1
12
Show member pathways
13.07 CDK2 CDK4 CDKN1A CHUK CREB1 CREBBP
13
Show member pathways
13.04 CDK2 CDKN1A CREBBP EP300 JUN
14
Show member pathways
13.02 ATF1 CHUK CREB1 IKBKB JUN NFKB1
15
Show member pathways
13.02 CREB1 CREBBP EP300 GLI2 JUN NFKB1
16
Show member pathways
13 ATF1 CHUK IKBKB JUN NFKB1
17
Show member pathways
13 CHUK CREBBP EP300 IKBKB JUN NFKB1
18
Show member pathways
12.99 CHUK CREBBP IKBKB JUN NFKB1
19
Show member pathways
12.98 CHUK CREB1 CREBBP EP300 IKBKB JUN
20
Show member pathways
12.95 CDK2 CDK4 CDKN1A CHUK CREB1 CREBBP
21
Show member pathways
12.93 CREB1 CREBBP EP300 IKBKB JUN NFKB1
22
Show member pathways
12.92 CDKN1A CHUK IKBKB JUN NFKB1
23
Show member pathways
12.89 CHUK CREB1 IKBKB JUN NFKB1
24
Show member pathways
12.89 ATF1 CDKN1A CHUK CREB1 IKBKB JUN
25
Show member pathways
12.88 CDK2 CDK4 CHUK CREBBP EP300 IKBKB
26
Show member pathways
12.84 CHUK CREBBP EP300 IKBKB NFKB1
27
Show member pathways
12.84 CDKN1A CHUK CREB1 IKBKB NFKB1
28
Show member pathways
12.81 CHUK CREBBP EP300 IKBKB NFKB1
29
Show member pathways
12.8 CHUK CREB1 CREBBP IKBKB JUN NFKB1
30
Show member pathways
12.73 CHUK CREB1 IKBKB JUN NFKB1
31
Show member pathways
12.73 CDKN1A CHUK CREBBP EP300 IKBKB NFKB1
32 12.7 CDK2 CDK4 CDKN1A CHUK CREB1 CRTC2
33
Show member pathways
12.67 CHUK IKBKB JUN NFKB1
34
Show member pathways
12.66 CDKN1A CHUK IKBKB NFKB1
35
Show member pathways
12.66 CHUK IKBKB JUN NFKB1
36
Show member pathways
12.65 CDK2 CDK4 CDKN1A CREB1
37 12.65 CDKN1A CREBBP EP300 IKBKB NFKB1
38
Show member pathways
12.63 CHUK IKBKB JUN NFKB1
39
Show member pathways
12.63 CREB1 CREBBP EP300 JUN NFKB1
40
Show member pathways
12.61 ATF1 CREB1 JUN NFKB1
41
Show member pathways
12.59 CHUK CREB1 CREBBP EP300 IKBKB JUN
42
Show member pathways
12.58 CHUK CREB1 IKBKB JUN NFKB1
43
Show member pathways
12.57 CHUK IKBKB JUN NFKB1
44
Show member pathways
12.57 CHUK CREBBP EP300 IKBKB NFKB1
45
Show member pathways
12.57 CHUK CREBBP EP300 IKBKB NFKB1
46 12.55 CDK2 CDK4 CHUK CREB1 CREBBP JUN
47 12.55 CDK2 CDK4 CDKN1A CHUK CREBBP EP300
48
Show member pathways
12.54 CHUK IKBKB JUN NFKB1
49
Show member pathways
12.54 CHUK CREB1 IKBKB JUN NFKB1
50
Show member pathways
12.54 CDK4 CHUK CREB1 IKBKB JUN NFKB1

GO Terms for Human T-Cell Leukemia Virus Type 1

Cellular components related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 nucleoplasm GO:0005654 9.47 ATF1 CDK2 CDK4 CDKN1A CHUK CREB1
2 cyclin-dependent protein kinase holoenzyme complex GO:0000307 9.43 CDK2 CDK4 CDKN1A
3 transcription factor complex GO:0005667 9.43 ATF1 CDK2 CDK4 CREB1 EP300 JUN
4 IkappaB kinase complex GO:0008385 9.37 CHUK IKBKB
5 CD40 receptor complex GO:0035631 9.32 CHUK IKBKB
6 cytoplasm GO:0005737 10.21 CDK2 CDK4 CDKN1A CHUK CREBBP CRTC2
7 cytosol GO:0005829 10.14 CDK2 CDK4 CDKN1A CHUK CRTC3 EP300
8 nucleus GO:0005634 10.03 ATF1 CDK2 CDK4 CDKN1A CHUK CREB1

Biological processes related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 31)
id Name GO ID Score Top Affiliating Genes
1 transcription from RNA polymerase II promoter GO:0006366 9.95 ATF1 CREB1 EP300 GLI2 JUN NFKB1
2 viral process GO:0016032 9.88 CREB1 CREBBP CRTC2 CRTC3 EP300 XPO1
3 Fc-epsilon receptor signaling pathway GO:0038095 9.86 CHUK IKBKB JUN NFKB1
4 response to drug GO:0042493 9.85 CDK4 CDKN1A CHUK CREB1 JUN XPO1
5 positive regulation of transcription, DNA-templated GO:0045893 9.81 CDK2 CHUK CREB1 CREBBP EP300 GLI2
6 response to toxic substance GO:0009636 9.8 CDK4 CDKN1A CHUK
7 G1/S transition of mitotic cell cycle GO:0000082 9.8 CDK2 CDK4 CDKN1A
8 Ras protein signal transduction GO:0007265 9.77 CDK2 CDKN1A JUN
9 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.76 CDK2 CDKN1A EP300
10 I-kappaB kinase/NF-kappaB signaling GO:0007249 9.75 CHUK IKBKB NFKB1
11 circadian rhythm GO:0007623 9.73 CDK4 CREB1 EP300 JUN
12 positive regulation of type I interferon production GO:0032481 9.72 CREBBP EP300 NFKB1
13 regulation of cell cycle GO:0051726 9.72 CDK2 CDK4 CDKN1A EP300 JUN
14 positive regulation of fibroblast proliferation GO:0048146 9.7 CDK4 CDKN1A JUN
15 positive regulation of DNA replication GO:0045740 9.69 ATF1 GLI2 JUN
16 response to hyperoxia GO:0055093 9.65 CDK4 CDKN1A
17 response to muscle stretch GO:0035994 9.65 JUN NFKB1
18 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.65 CHUK CREBBP EP300 IKBKB NFKB1
19 positive regulation by host of viral transcription GO:0043923 9.64 EP300 JUN
20 positive regulation of CREB transcription factor activity GO:0032793 9.64 CRTC2 CRTC3
21 stress-activated MAPK cascade GO:0051403 9.63 CHUK IKBKB NFKB1
22 I-kappaB phosphorylation GO:0007252 9.62 CHUK IKBKB
23 protein acetylation GO:0006473 9.61 CREBBP EP300
24 N-terminal peptidyl-lysine acetylation GO:0018076 9.49 CREBBP EP300
25 response to organic substance GO:0010033 9.43 CDK2 CDK4 CDKN1A CHUK CREB1 JUN
26 positive regulation of transcription from RNA polymerase II promoter GO:0045944 9.36 ATF1 CHUK CREB1 CREBBP CRTC2 CRTC3
27 regulation of transcription, DNA-templated GO:0006355 10.24 ATF1 CREB1 CREBBP CRTC2 CRTC3 EP300
28 transcription, DNA-templated GO:0006351 10.22 ATF1 CREB1 CREBBP CRTC2 CRTC3 EP300
29 protein phosphorylation GO:0006468 10.03 CDK2 CDK4 CHUK CREB1 IKBKB
30 negative regulation of transcription from RNA polymerase II promoter GO:0000122 10.01 CDK2 CREBBP EP300 GLI2 NFKB1 XPO1
31 negative regulation of apoptotic process GO:0043066 10 CDKN1A GLI2 IKBKB JUN NFKB1

Molecular functions related to Human T-Cell Leukemia Virus Type 1 according to GeneCards Suite gene sharing:

(show all 20)
id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.99 CDK2 CDK4 CDKN1A CHUK IKBKB
2 sequence-specific DNA binding GO:0043565 9.95 ATF1 CREB1 GLI2 JUN NFKB1
3 protein heterodimerization activity GO:0046982 9.92 ATF1 CHUK IKBKB JUN NFKB1
4 transcription regulatory region DNA binding GO:0044212 9.81 CREB1 GLI2 JUN NFKB1
5 transcription factor activity, RNA polymerase II distal enhancer sequence-specific binding GO:0003705 9.65 ATF1 CREB1 JUN
6 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0000980 9.63 CREB1 JUN NFKB1
7 chromatin binding GO:0003682 9.63 CREBBP CRTC2 EP300 GLI2 JUN NFKB1
8 transcription cofactor activity GO:0003712 9.61 CREB1 CREBBP EP300
9 transcriptional activator activity, RNA polymerase II transcription factor binding GO:0001190 9.58 CREB1 JUN
10 regulatory region DNA binding GO:0000975 9.58 CREB1 NFKB1
11 acetyltransferase activity GO:0016407 9.57 CREBBP EP300
12 cAMP response element binding GO:0035497 9.54 CREB1 JUN
13 cyclin-dependent protein serine/threonine kinase activity GO:0004693 9.54 CDK2 CDK4 CDKN1A
14 cAMP response element binding protein binding GO:0008140 9.49 CRTC2 CRTC3
15 cyclin binding GO:0030332 9.43 CDK2 CDK4 CDKN1A
16 transcription factor binding GO:0008134 9.43 CREB1 CREBBP EP300 GLI2 JUN NFKB1
17 IkappaB kinase activity GO:0008384 9.4 CHUK IKBKB
18 peptide N-acetyltransferase activity GO:0034212 9.32 CREBBP EP300
19 RNA polymerase II activating transcription factor binding GO:0001102 8.92 CREB1 CREBBP EP300 JUN
20 transcription factor activity, sequence-specific DNA binding GO:0003700 10.03 ATF1 CREB1 CREBBP GLI2 JUN NFKB1

Sources for Human T-Cell Leukemia Virus Type 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....